Vandortuzumab vedotin
Monoclonal antibody
- none
- 1471985-92-8
- none
- 44OUQ00D1U
- D11002
Vandortuzumab vedotin (INN; development code RG7450) is a humanized monoclonal antibody designed for the treatment of cancer.[1][2]
This drug was developed by Genentech/Roche. Development was discontinued in 2017.[3]
References
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Vandortuzumab Vedotin, American Medical Association.
- ^ World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 112" (PDF). WHO Drug Information. 28 (4).
- ^ "Vandortuzumab vedotin". AdisInsight. Springer Nature Switzerland AG.
- v
- t
- e
Monoclonal antibodies for tumors
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e